The global prevalence of MASLD is substantial, with estimates ranging from 30% to 32%, and the incidence of associated conditions like liver ... of fat storage. GLP-1 receptor agonists (GLP ...

Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...

Some preclinical studies and human case reports have found glucagon-like peptide-1 receptor (GLP-1) agonists reduced alcohol consumption, though they are only approved for diabetes and obesity ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Some preclinical studies and human case reports have found glucagon-like peptide-1 receptor (GLP-1) agonists reduced alcohol consumption, though they are only approved for diabetes and obesity ...

The global prevalence of MASLD is substantial, with estimates ranging from 30% to 32%, and the incidence of associated conditions like liver fibrosis is expected ... and the modulation of fat storage.

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...